{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T04:13:10Z","timestamp":1747973590521,"version":"3.41.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,22]]},"DOI":"10.7759\/cureus.84617","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T14:38:19Z","timestamp":1747924699000},"source":"Crossref","is-referenced-by-count":0,"title":["Remission of Chimeric Antigen Receptor T-Cell-Refractory Diffuse Large B-Cell Lymphoma Resolved by Surgery and CD20 Bispecific Therapy"],"prefix":"10.7759","author":[{"given":"Vinny","family":"Lococo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Selby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Woodroof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Forat","family":"Lutfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2023.11.004","article-title":"Epidemiology and etiology of diffuse large B-cell lymphoma","volume":"60","author":"Wang SS","year":"2023","unstructured":"Wang SS. Epidemiology and etiology of diffuse large B-cell lymphoma. Semin Hematol. 2023, 60:255-66. 10.1053\/j.seminhematol.2023.11.004","journal-title":"Semin Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-018-0555-8","article-title":"Extranodal diffuse large B cell lymphoma: molecular features, prognosis, and risk of central nervous system recurrence","volume":"19","author":"Ollila TA","year":"2018","unstructured":"Ollila TA, Olszewski AJ. Extranodal diffuse large B cell lymphoma: molecular features, prognosis, and risk of central nervous system recurrence. Curr Treat Options Oncol. 2018, 19:38. 10.1007\/s11864-018-0555-8","journal-title":"Curr Treat Options Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000185","article-title":"CAR-T cell therapy in diffuse large B cell lymphoma: hype and hope","volume":"3","author":"Hopfinger G","year":"2019","unstructured":"Hopfinger G, J\u00e4ger U, Worel N. CAR-T cell therapy in diffuse large B cell lymphoma: hype and hope. Hemasphere. 2019, 3:e185. 10.1097\/HS9.0000000000000185","journal-title":"Hemasphere"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01594-x","article-title":"Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed\/refractory large B-cell lymphoma","volume":"17","author":"Rosenthal A","year":"2024","unstructured":"Rosenthal A, Munoz J, Jun M, et al.. Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed\/refractory large B-cell lymphoma. J Hematol Oncol. 2024, 17:69. 10.1186\/s13045-024-01594-x","journal-title":"J Hematol Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.184192","article-title":"Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy","volume":"103","author":"de Charette M","year":"2018","unstructured":"de Charette M, Houot R. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica. 2018, 103:1256-68. 10.3324\/haematol.2017.184192","journal-title":"Haematologica"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet L","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, et al.. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014, 66:2613-20. 10.1002\/art.38690","journal-title":"Arthritis Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci L","year":"2018","unstructured":"Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma. Blood. 2018, 131:2307-19. 10.1182\/blood-2017-11-764332","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al.. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016, 127:2375-90. 10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma","volume":"87","author":"Martelli M","year":"2013","unstructured":"Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013, 87:146-71. 10.1016\/j.critrevonc.2012.12.009","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.197","article-title":"Diffuse large B-cell lymphoma-treatment approaches in the molecular era","volume":"11","author":"Roschewski M","year":"2014","unstructured":"Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014, 11:12-23. 10.1038\/nrclinonc.2013.197","journal-title":"Nat Rev Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jscr\/rjae453","article-title":"Primary diffuse large B-cell lymphoma of the lacrimal sac with involvement of maxillary sinus: a case report and review of literature","volume":"2024","author":"Sadhar B","year":"2024","unstructured":"Sadhar B, Slupek D, Steehler A, Denne C, Steehler K. Primary diffuse large B-cell lymphoma of the lacrimal sac with involvement of maxillary sinus: a case report and review of literature. J Surg Case Rep. 2024, 2024:rjae453. 10.1093\/jscr\/rjae453","journal-title":"J Surg Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77507","article-title":"Diffuse large B-cell lymphoma causing central airway obstruction: a case report","volume":"17","author":"Shrestha R","year":"2025","unstructured":"Shrestha R, Khadka S, Saunders H, Helgeson S. Diffuse large B-cell lymphoma causing central airway obstruction: a case report. Cureus. 2025, 17:e77507. 10.7759\/cureus.77507","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900715)66:2<267::aid-cncr2820660213>3.0.co;2-n","article-title":"Surgical debulking is associated with improved survival in stage I-II diffuse large cell lymphoma","volume":"66","author":"Romagurea JE","year":"1990","unstructured":"Romagurea JE, Velasquez WS, Silvermintz KB, Fuller LB, Hagemeister FB, McLaughlin P, Cabanillas F. Surgical debulking is associated with improved survival in stage I-II diffuse large cell lymphoma. Cancer. 1990, 66:267-72. 10.1002\/1097-0142(19900715)66:2&lt;267::aid-cncr2820660213&gt;3.0.co;2-n","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10260","article-title":"Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma","volume":"94","author":"Wilder RB","year":"2002","unstructured":"Wilder RB, Romaguera JE, Tucker SL, Ha CS, Hess MA, Cabanillas F, Cox JD. Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma. Cancer. 2002, 94:601-5. 10.1002\/cncr.10260","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3448","article-title":"Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy","volume":"9","author":"Schmitz C","year":"2020","unstructured":"Schmitz C, Rekowski J, M\u00fcller SP, et al.. Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy. Cancer Med. 2020, 9:8386-96. 10.1002\/cam4.3448","journal-title":"Cancer Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/369166-remission-of-chimeric-antigen-receptor-t-cell-refractory-diffuse-large-b-cell-lymphoma-resolved-by-surgery-and-cd20-bispecific-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T14:38:20Z","timestamp":1747924700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/369166-remission-of-chimeric-antigen-receptor-t-cell-refractory-diffuse-large-b-cell-lymphoma-resolved-by-surgery-and-cd20-bispecific-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.84617","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}